| Description : |
PI3K-C2α protein belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. The PI3-kinase activity of this protein is not sensitive to nanomolar levels of the inhibitor wortmanin. This protein was shown to be able to be activated by insulin and may be involved in integrin-dependent signaling. |
| Source : |
Sf21 |
| Species : |
Human |
| Tag : |
His |
| Protein length : |
299–end |
| Form : |
0.76mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol, 20mM β-glycerophosphate, 0.25mM Na3VO4, 10mM NaF. Frozen solution. |
| Bio-activity : |
164U/mg, where one unit of PI3K-C2α, active activity is defined as 1nmol phosphatidylinositol 3-phosphate (PI(3)P) formed per minute at room temperature with a final ATP concentration of 200μM. |
| Molecular Mass : |
161 kDa |
| AA Sequence : |
1 MSYYHHHHHH DYDIPTTENL YFQGAMLAKD PWDAVLLEER STANCHLERK VNGKSLSVAT 61 VTRSQSLNIR TTQLAKAQGH ISQKDPNGTS SLPTGSSLLQ EVEVQNEEMA AFCRSITKLK 121 TKFPYTNHRT NPGYLLSPVT AQRNICGENA SVKVSIDIEG FQLPVTFTCD VSSTVEIIIM 181 QALCWVHDDL NQVDVGSYVL KVCGQEEVLQ NNHCLGSHEH IQNCRKWDTE IRLQLLTFSA 241 MCQNLARTAE DDETPVDLNK HLYQIEKPCK EAMTRHPVEE LLDSYHNQVE LALQIENQHR 301 AVDQVIKAVR KICSALDGVE TLAITESVKK LKRAVNLPRS KTADVTSLFG GEDTSRSSTR 361 GSLNPENPVQ VSINQLTAAI YDLLRLHANS GRSPTDCAQS SKSVKEAWTT TEQLQFTIFA 421 AHGISSNWVS NYEKYYLICS LSHNGKDLFK PIQSKKVGTY KNFFYLIKWD ELIIFPIQIS 481 QLPLESVLHL TLFGILNQSS GSSPDSNKQR KGPEALGKVS LPLFDFKRFL TCGTKLLYLW 541 TSSHTNSVPG TVTKKGYVME RIVLQVDFPS PAFDIIYTTP QVDRSIIQQH NLETLENDIK 601 GKLLDILHKD SSLGLSKEDK AFLWEKRYYC FKHPNCLPKI LASAPNWKWV NLAKTYSLLH 661 QWPALYPLIA LELLDSKFAD QEVRSLAVTW IEAISDDELT DLLPQFVQAL KYEIYLNSSL 721 VQFLLSRALG NIQIAHNLYW LLKDALHDVQ FSTRYEHVLG ALLSVGGKRL REELLKQTKL 781 VQLLGGVAEK VRQASGSARQ VVLQRSMERV QSFFQKNKCR LPLKPSLVAK ELNIKSCSFF 841 SSNAVPLKVT MVNADPMGEE INVMFKVGED LRQDMLALQM IKIMDKIWLK EGLDLRMVIF 901 KCLSTGRDRG MVELVPASDT LRKIQVEYGV TGSFKDKPLA EWLRKYNPSE EEYEKASENF 961 IYSCAGCCVA TYVLGICDRH NDNIMLRSTG HMFHIDFGKF LGHAQMFGSF KRDRAPFVLT 1021 SDMAYVINGG EKPTIRFQLF VDLCCQAYNL IRKQTNLFLN LLSLMIPSGL PELTSIQDLK 1081 YVRDALQPQT TDAEATIFFT RLIESSLGSI ATKFNFFIHN LAQLRFSGLP SNDEPILSFS 1141 PKTYSFRQDG RIKEVSVFTY HKKYNPDKHY IYVVRILREG QIEPSFVFRT FDEFQELHNK 1201 LSIIFPLWKL PGFPNRMVLG RTHIKDVAAK RKIELNSYLQ SLMNASTDVA ECDLVCTFFH 1261 PLLRDEKAEG IARSADAGSF SPTPGQIGGA VKLSISYRNG TLFIMVMHIK DLVTEDGADP 1321 NPYVKTYLLP DNHKTSKRKT KISRKTRNPT FNEMLVYSGY SKETLRQREL QLSVLSAESL 1381 RENFFLGGVT LPLKDFNLSK ETVKWYQLTA ATYL |
| Purity : |
Purity 72% by SDS-PAGE and Coomassie blue staining. |
| Applications : |
Drug Discovery & Development |
| Storage : |
6 months at -70 centigrade. |
| Handling Advice : |
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade. |
| Use/Stability : |
On receipt of material store at -70 centigrade. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap. |
